Expression profile and promoter analysis of HEPIS

  • Authors:
    • Fen Hu
    • Yunfeng Zhang
  • View Affiliations

  • Published online on: October 25, 2017     https://doi.org/10.3892/etm.2017.5374
  • Pages:569-575
Metrics: HTML 0 views | PDF 0 views
0

Abstract

Human embryo lung cellular protein interacting with severe acute respiratory syndrome‑coronavirus nonstructural protein‑10 (HEPIS) is a novel transcriptional repressor, the expression profile and promoter activity of which have not been well studied. In the present study, in situ hybridization of RNA was used to study differential HEPIS expression levels in different types of cancer and normal tissues. A total of six truncated lengths of the HEPIS promoter regulatory sequences were cloned into the pGL3‑basic vector, and reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and dual luciferase reporter assays were performed. The results of RT‑qPCR demonstrated that HEPIS expression levels differed across four breast cancer cell lines. The results of the dual luciferase reporter assays revealed that the activities of the reporter gene fragments spanning ‑1334/+373, ‑1203/+373, ‑1060/+373 and ‑899/+373 bp were higher compared with the reporter gene fragments spanning ‑759/+373 and ‑279/+373 bp. A search of the transcription factor database TRANSFAC identified numerous octamer transcription factor‑1 (OCT‑1), nuclear factor (NF)‑κB and C‑JUN transcription factor binding sites located on the HEPIS promoter (pHEPIS). Furthermore, the results revealed that mutations of the OCT‑1 (‑1236/‑1223 bp), NF‑κB (‑1186/‑1176 bp) and C‑JUN (‑856/‑846 bp) sites on the human pHEPIS resulted in a decrease in luciferase activity. A chromatin immunoprecipitation assay revealed that OCT‑1, NF‑κB and C‑JUN bound to pHEPIS in a site‑dependent manner at the basal state. The TRANSFAC database was used to analyze the pHEPIS of multiple species and several activator protein‑1, NF‑κB and OCT‑1 transcription factor binding sites were predicted. In conclusion, the results of the present study suggest that HEPIS is expressed at different levels in multiple organs and breast cancer cell lines. Furthermore, these findings indicate that OCT‑1, NF‑κB and C‑JUN transcription factors are associated with transcriptional regulation of the HEPIS gene.

Related Articles

Journal Cover

January 2018
Volume 15 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

2016 Impact Factor: 1.261
Ranked #50/128 Medicine Research and Experimental
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Hu, F., & Hu, F. (2018). Expression profile and promoter analysis of HEPIS. Experimental and Therapeutic Medicine, 15, 569-575. https://doi.org/10.3892/etm.2017.5374
MLA
Hu, F., Zhang, Y."Expression profile and promoter analysis of HEPIS". Experimental and Therapeutic Medicine 15.1 (2018): 569-575.
Chicago
Hu, F., Zhang, Y."Expression profile and promoter analysis of HEPIS". Experimental and Therapeutic Medicine 15, no. 1 (2018): 569-575. https://doi.org/10.3892/etm.2017.5374